Revenio Group Corporation: Icare and Iridex Corporation enter into distribution cooperation

Revenio Group Corporation, Stock Exchange Release, May 18, 2015 at 9:00

ICARE AND IRIDEX CORPORATION ENTER INTO DISTRIBUTION COOPERATION

Revenio Group Corporation's subsidiary Icare Finland Plc has signed a distribution agreement with US-based Iridex Corporation related to Icare's TA01i instrument. Iridex plans to package the Icare TA01i with the Iridex Total Glaucoma Solution which includes the newly launched Cyclo G6 laser and the proprietary MicroPulse® P3 device dedicated specifically to treat patients diagnosed with a range of glaucoma disease states. The Icare TA01i aids the physician in the diagnosis of glaucoma as well as post-operative assessment and monitoring of the patient's intra-ocular pressure.

Iridex sold its first new Cyclo G6 glaucoma laser along with MicroPulse® P3 disposable devices during the first quarter of 2015. The MicroPulse® P3 device offers a repeatable, minimally invasive approach to slowing the progress of the disease and pushing off the need for more invasive surgical intervention. The Icare TA01i tonometer revolutionizes effective, early glaucoma detection by making the intra-ocular pressure measuring routine quick and easy for the patient as well as the physician.

"Cooperation with Iridex broadens the market reach of both organizations where the Icare and Iridex equipment and disposables may be offered to glaucoma physicians as part of a complete system. Iridex, as well as Icare are well-known brands within the ophthalmic community and we expect positive cooperation during the years to come," states Revenio's CEO Olli-Pekka Salovaara.

For further information, please contact:
President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ OMX Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi

Iridex Corporation in brief

IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. In addition to the US, Iridex markets its products through distributors to over 100 countries. The Iridex's revenues totaled to USD 42.8 million in 2014 and the shares of the Corporation are listed on NASDAQ Global Market. www.iridex.com

The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis screening and monitoring. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology lies on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki. www.revenio.fi